Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Revenue (2018 - 2023)

Historic Revenue for Denali Therapeutics (DNLI) over the last 6 years, with Q3 2023 value amounting to $1.3 million.

  • Denali Therapeutics' Revenue fell 6440.01% to $1.3 million in Q3 2023 from the same period last year, while for Jun 2024 it was $1.3 million, marking a year-over-year decrease of 9963.07%. This contributed to the annual value of $330.5 million for FY2023, which is 20474.08% up from last year.
  • Denali Therapeutics' Revenue amounted to $1.3 million in Q3 2023, which was down 6440.01% from $294.1 million recorded in Q2 2023.
  • Denali Therapeutics' Revenue's 5-year high stood at $316.8 million during Q4 2020, with a 5-year trough of $1.3 million in Q3 2023.
  • In the last 5 years, Denali Therapeutics' Revenue had a median value of $9.4 million in 2020 and averaged $44.3 million.
  • As far as peak fluctuations go, Denali Therapeutics' Revenue tumbled by 9628.25% in 2019, and later skyrocketed by 668114.3% in 2020.
  • Over the past 5 years, Denali Therapeutics' Revenue (Quarter) stood at $4.7 million in 2019, then surged by 6681.14% to $316.8 million in 2020, then plummeted by 96.05% to $12.5 million in 2021, then decreased by 17.83% to $10.3 million in 2022, then tumbled by 87.68% to $1.3 million in 2023.
  • Its Revenue was $1.3 million in Q3 2023, compared to $294.1 million in Q2 2023 and $35.1 million in Q1 2023.